Frontiers in Molecular Neuroscience (Oct 2022)

Clinical application of prion-like seeding in α-synucleinopathies: Early and non-invasive diagnosis and therapeutic development

  • Jiaqi Li,
  • Jiaqi Li,
  • Haiyang Luo,
  • Haiyang Luo,
  • Haiyang Luo,
  • Honglin Zheng,
  • Honglin Zheng,
  • Suying Duan,
  • Suying Duan,
  • Taiqi Zhao,
  • Taiqi Zhao,
  • Yanpeng Yuan,
  • Yanpeng Yuan,
  • Yutao Liu,
  • Yutao Liu,
  • Xiaoyun Zhang,
  • Xiaoyun Zhang,
  • Yangyang Wang,
  • Yangyang Wang,
  • Jing Yang,
  • Jing Yang,
  • Jing Yang,
  • Yuming Xu,
  • Yuming Xu,
  • Yuming Xu

DOI
https://doi.org/10.3389/fnmol.2022.975619
Journal volume & issue
Vol. 15

Abstract

Read online

The accumulation and deposition of misfolded α-synuclein (α-Syn) aggregates in the brain is the central event in the pathogenesis of α-synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and multiple-system atrophy. Currently, the diagnosis of these diseases mainly relies on the recognition of advanced clinical manifestations. Differential diagnosis among the various α-synucleinopathies subtypes remains challenging. Misfolded α-Syn can template its native counterpart into the same misfolded one within or between cells, behaving as a prion-like seeding. Protein-misfolding cyclic amplification and real-time quaking-induced conversion are ultrasensitive protein amplification assays initially used for the detection of prion diseases. Both assays showed high sensitivity and specificity in detection of α-synucleinopathies even in the pre-clinical stage recently. Herein, we collectively reviewed the prion-like properties of α-Syn and critically assessed the detection techniques of α-Syn-seeding activity. The progress of test tissues, which tend to be less invasive, is presented, particularly nasal swab, which is now widely known owing to the global fight against coronavirus disease 2019. We highlight the clinical application of α-Syn seeding in early and non-invasive diagnosis. Moreover, some promising therapeutic perspectives and clinical trials targeting α-Syn-seeding mechanisms are presented.

Keywords